29 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 591

FY Ads Singapore: The Business Matchmaker Behind Trip.com, Haidilao Singapore, and Sichuan Airlines’ Iconic Chengdu Campaign

SINGAPORE, March 28, 2025 /PRNewswire/ — What happens when you bring together the excitement of travel, the irresistible appeal of hotpot, and the dynamic energy of Chengdu? You get a campaign that’s not only memorable but legendary. At FY Ads Singapore, we didn’t just organize an event – we acted as the business matchmaker between Trip.com, Haidilao Singapore, and Sichuan Airlines, creating an unforgettable cross-brand collaboration that captivated audiences both online and offline. Here’s how we brought this groundbreaking partnership to life.

Transforming Ideas into Impactful Experiences

Our mission was simple: establish Chengdu as a must-visit destination while highlighting the experiences offered by Trip.com, the culinary excellence of Haidilao Singapore, and the seamless travel service of Sichuan Airlines. The real challenge? Fostering a collaboration between these three brands and bringing their visions together. That’s where FY Ads came in as the business matchmaker, aligning their unique strengths to create a unified and powerful campaign.

The Strategy Behind the Success

Dream Big, Plan Smart

The foundation of our approach was based on creating synergy between the brands, with careful planning and attention to detail:

  • Thematic Brilliance: A campaign theme that intertwined Chengdu’s rich culture, exciting travel possibilities with Trip.com and Sichuan Airlines, and the vibrant dining culture of Haidilao Singapore.
  • Business Matchmaking: As the catalyst for this cross-brand collaboration, FY Ads played a crucial role in connecting the right brands at the right time, ensuring their offerings complemented each other perfectly.
  • Meticulous Planning: We took charge of every aspect, ensuring that each brand’s vision came to life seamlessly across all touchpoints, from online to offline engagement.

Creating Visuals That Captivate

The visuals were essential in driving the campaign’s success. Here’s how we brought it all together:

  • Immersive Event Designs: The physical event spaces were designed to reflect the unique aspects of each brand, with interactive setups that highlighted the cultural richness of Chengdu, the travel experience offered by Sichuan Airlines and Trip.com, and the mouthwatering dining experiences from Haidilao Singapore.
  • Co-branded Landing Page: A dynamic and user-friendly landing page that integrated the campaign theme while showcasing the collaboration between the three brands.
  • Social Media Masterpieces: High-quality videos, photos, and content that were perfectly tailored for platforms like Instagram and Xiaohongshu, amplifying the reach of the campaign online.

Flawless Execution On-Site and Online

When it comes to delivering an event that blends both physical and digital experiences, we take no shortcuts. Here’s how we ensured success:

  • On-Site Precision: We managed every detail of the offline event with precision – from the initial setup to real-time coordination, ensuring a smooth flow that highlighted the contributions of all three brands.
  • Online Amplification: We didn’t stop at the physical event – FY Ads ensured that the campaign reached a global audience through strategic online initiatives. By partnering with influencers, securing media placements, and driving content through social media, we maximized online engagement and visibility for Trip.com, Haidilao Singapore, and Sichuan Airlines.

Amplifying the Buzz Online and Beyond

To ensure the campaign had a far-reaching impact, we focused on both online and offline amplification:

  • Influencer Partnerships: We worked with influencers who authentically represented the campaign’s spirit, helping to drive genuine excitement for the collaboration between Trip.com, Haidilao Singapore, and Sichuan Airlines.
  • Media Placements: We secured high-value media placements in leading publications, ensuring the campaign was showcased in front of the right audiences both offline and online.
  • Social Media Campaigns: By curating engaging content and encouraging user-generated posts, we made sure the campaign stayed top of mind for audiences long after the event.

The Power Behind the Campaign’s Success

This wasn’t just an event – it was a powerful cross-brand collaboration made possible by FY Ads. By blending the strengths of Trip.com, Haidilao Singapore, and Sichuan Airlines, we were able to:

  • Showcase Chengdu as a must-visit destination, merging travel and dining in an innovative way.
  • Elevate the visibility of Trip.com, Haidilao Singapore, and Sichuan Airlines, ensuring each brand’s unique offering was front and center.
  • Drive sustained buzz and engagement, both online and offline, through strategic planning, influencer partnerships, and media placements.

Why FY Ads is Your Ideal Partner

At FY Ads, we don’t just plan events – we create extraordinary, cross-brand collaborations that resonate with audiences. Acting as the business matchmaker, we connect the right brands and bring their visions together in ways that are impactful and memorable. From crafting visually captivating experiences to amplifying campaigns online and offline, we ensure every project achieves its full potential.

Ready to create a campaign that will make waves? Let’s chat about how we can bring your vision to life and turn your next project into an unforgettable experience.

 

The Future of Oil: Market Trends, Risks, and Trading Potential with Octa Broker


KUALA LUMPUR, MALAYSIA – Media OutReach Neswire – 28 March 2025 – As of March 2025, Brent crude oil prices have experienced fluctuations: its price traded between $68.30 and slightly above $73 per barrel. This volatility reflects evolving macroeconomic factors and geopolitical dynamics. OPEC+ has announced plans to gradually increase oil production starting in April 2025, aiming to unwind 2.2 million barrels per day of previous cuts over an 18-month period. Despite global efforts to transition towards renewable energy sources, oil continues to play a pivotal role in the global economy. Octa Broker, a broker with globally recognised licenses, discusses the potential attractiveness of investments in oil in 2025 and the risks to consider.

Octa Broker
Octa Broker

Oil Price Forecasts for 2025: Expert Predictions

Oil can become a lucrative trade option in 2025. The U.S. Energy Information Administration (EIA) projects Brent crude oil prices to average $74 per barrel in 2025 and decline to $68 per barrel in 2026. Pickering Energy Partners’ Chief Investment Officer, Dan Pickering, expects oil prices to range between $65 and $75 per barrel in 2025 amid ongoing supply tightness and geopolitical risks.

According to Kar Yong Ang, financial market analyst at Octa Broker, oil remains a core asset for traders looking to hedge against inflation and geopolitical risk. He says that ‘Oil‘s price movements in 2025 will be shaped by supply-side decisions from OPEC+ and the geopolitical landscape. Traders should be prepared for volatility but also recognise the potential for trading opportunities in these market conditions.’ Global oil demand is projected to rise by 1.4 million barrels per day in 2025, driven by strong air travel and automotive demand. However, economic uncertainties, including tariff disputes and potential recession fears, have introduced near-term instability in the oil market.

Factors Affecting Oil Prices

Geopolitical tensions continue to be a leading force in the oil market. The current political tension and conflict in the principal areas of oil production can affect supply chains. Despite tensions simmering in the Middle East, strong global oil supply is keeping prices from shooting spectacularly.

OPEC+ remains the world’s dominant oil supplier, recently indicating a willingness to increase production—an outlook that can put pressure on prices. But non-OPEC producers, particularly U.S. shale firms, are significant as well. While U.S. production remains robust, its growth rate has slowed compared to recent years.

On the demand side, China remains the largest crude oil consumer, but its slowing economy is making the sector apprehensive about future demand. India, on its part, is continuing to exhibit healthy demand, underpinning market stability, while the U.S. is contributing to potential headwinds powered by tariff-related economic pressure. These supply-side-leading dynamics will play out with demand-side uncertainty and set the trajectory of the petroleum market over the next few months.

Oil Investment Potential in 2025 and Associated Risks

Oil has historically been a trusted inflation hedge, but in 2025 its direction is not at all obvious. The market is being pulled in two opposite directions by a mix of economic and geopolitical pressures, each with the power to move prices a lot.

On the downside, the spectre of a worldwide economic slowdown threatens the market. New tariffs and increasing trade tensions have the power to sap demand and therefore pull oil prices lower. Crude can plummet sharply if it turns for the worse, and a full-fledged recession sets in. Meanwhile, Middle East instability is building, and with Iran becoming increasingly involved, the risk of supply disruptions is increasing. If it escalates further, oil can come back hard.

OPEC has also complicated matters. The cartel has been increasing production, expecting demand to rise as well, but there is a very real chance that they overestimated. When demand doesn’t rise as much as hoped, the market is in an oversupply situation, and prices will be falling again.

And then there is the longer-term transformation. The worldwide push towards renewables is slowly reshaping energy markets, and while the transition won’t be instantaneous, it’s already tightening the screws on oil demand. Prices might not react in the near term, but the handwriting is on the wall.

Meanwhile, U.S. shale, once the biggest wild card in global oil supply, is no longer the unstoppable force that it was. Production is still robust, but growth has slowed, and most believe that the industry has already peaked. That is one reason that can potentially keep prices underpinned in the long term.

Weak demand forecasts by China were one of the key drivers of oil prices in 2024. In 2025 political tensions might give rise to supply shocks resulting in surprise price peaks, making oil a good option as a short-term trade. In the long term, the asset price may remain relatively stable or even decrease, as expected by the experts.

However, traders must balance risks before they invest, even in the short term. Oil prices are highly sensitive to geopolitical tensions, which may usher in unexpected price swings. Recessions in large economies, particularly China, may dampen demand, while the global shift towards alternative energy sources is a long-term threat to the supremacy of oil. In addition, overproduction by the oil-producing nations may result in lower prices and render it unprofitable for investors.

The Role of Oil in the Global Energy Transition

Oil companies are still expanding their portfolios into renewable energy investments, showing heightened interest in sustainability. Investment in clean energy by oil and gas companies rose to approximately USD 30 billion in 2023, which accounts for less than 4% of their overall capital expenditure. Notably, over 60% of this investment came from just four major companies: Equinor, TotalEnergies, Shell, and BP, highlighting that a small group of industry leaders are spearheading the transition. This push into wind, solar, and hydrogen investments, alongside continued oil production, provides new opportunities for traders to diversify their portfolios with both conventional energy assets and new renewables.

Practical Recommendations for Traders and Investors

To successfully trade the oil market in 2025, investors and traders can consider the following tips:

  1. Stay Informed on Market Fundamentals. For example, follow news regarding the key drivers of oil prices. To track oil prices effectively, focus on primary short-term influences. Geopolitical threats, especially in Ukraine and the Middle East, are sudden market changes. Central bank forecasts and interest rate manoeuvres influence demand macroeconomically. Political steps — tariffs, and sanctions — affect prices as well. Additionally, track EIA stockpile reports, also IEA and OPEC bulletins. These reports offer valuable insights into global energy supply and demand dynamics, allowing for a more comprehensive understanding of market trends and potential price fluctuations.
  2. Utilise Diverse Trading Instruments like ETFs or CFDs. The latter allows traders to speculate on the future movement of oil prices without having to own the underlying commodity, hence requiring smaller investments. ​
  3. Implement Robust Risk Management Strategies. Due to the high volatility of oil markets, effective risk management must be employed. This includes stop-loss orders, take-profits, portfolio diversification, and position sizing, which is advised not to exceed 1-2% of capital per trade.

2025 oil markets are a complex mix of risk and opportunity. Macro drivers such as world economic growth patterns and the pace towards renewables will drive medium- and long-term demand curves, but geopolitical tensions and supply-side pressures can underpin high price levels. Those who enter the market with a sophisticated research strategy — balancing fundamental and technical factors — will be well-equipped to navigate this changing landscape.

Oil companies’ ability to make renewable investments alongside traditional energy production highlights the sector’s ongoing development. Short-term volatility can be leveraged for tactical gains by traders, but long-term investors must ride the structural adjustments that are likely to define the industry for the next two decades. Good risk management, continuous market studies, and diversification in exposure will remain the keys to success as the energy sector evolves.

Disclaimer: Trading involves risks and may not be suitable for all investors. Use your expertise wisely and evaluate all associated risks before making an investment decision
Hashtag: #Octa

The issuer is solely responsible for the content of this announcement.

Octa

is an international CFD broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including the improvement of educational infrastructure and short-notice relief projects supporting local communities.

In Southeast Asia, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.

Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

SAP-001 is Shanton’s lead investigational compound with First- and Best-in-Class potential in uncontrolled gout

SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ — Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a Phase 2b study in refractory gout patients with its investigational drug SAP-001 that uses a First-in-Class Mechanism of Action targeting a distinct kidney transporter.

“We are excited and very pleased with the outcome of our Phase 2b clinical study in this difficult-to-treat population of refractory gout patients” says Dr. Bing Li, Shanton’s CEO. “By the end of month 3 in our study, nearly 100% of patients that were confirmed exposed to daily SAP-001 30 and 60 mg dosages on top of conventional therapy reached the study’s therapeutical target (serum uric acid levels below 6mg/dL), compared to only about 10% of patients on conventional treatment who reached that goal. The majority of treatment effects persisted until the end of treatment at month 6 of the study. More than half of those patients confirmed exposed to a daily 60 mg dose reached serum uric acid levels below 3mg/dL. Importantly, the study demonstrated an excellent safety profile in this population.”

Shanton’s gout program already showed excellent, best-in-class efficacy compared to other Urate Lowering Therapies in prior Phase 1 and 2a studies in regular gout patients, an outcome that has now been repeated in the challenging target population of refractory patients that often have a more severe form of gout with limited treatment options. Dr. Wenfeng Miao, Shanton’s CMO adds: “This is the first successful clinical study with an oral gout drug to treat these refractory patients that normally need to be treated with an intravenous uricase. The efficacy of SAP-001 in this population is very impressive in all dosage groups at all assessed time points across the six months of treatment. We believe that the excellent efficacy and safety outcomes in this study show the exciting potential of our First-in-Class compound with its novel mechanism of action (MOA) that selectively targets a distinct kidney transporter for urate lowering treatment. The medical community has long been looking for this new mechanism in gout to address the shortcomings with conventional MOAs, especially where it comes to treating refractory and tophaceous patients. Our goal is to proceed into pivotal studies with our program later this year to eventually offer a paradigm-shifting gout treatment to our patients and make a big impact in their lives.”

About Gout

Gout is the most common form of inflammatory arthritis and the second most prevalent metabolic disease. It is caused by too much uric acid in the bloodstream, with over 12 million adult patients diagnosed in the US alone.1 Hyperuricemia, elevated serum uric acid levels, can over time result in gout when urate crystals are deposited in joints and other body tissues, causing inflammatory responses and painful gout attacks (flares). Recurrent gout flares are debilitating, and chronic gouty arthritis can over time lead to joint destruction and joint disfigurement.

About 29% of diagnosed gout patients in the US are treated with urate lowering therapies (ULTs), but only half of those patients sufficiently respond to or can tolerate current treatment options. It is estimated that up to 20% of US gout patients on standard-of-care allopurinol or febuxostat are physiologically refractory to these treatments. 2,3

About Shanton’s Phase 2b Gout Study

Shanton’s Phase 2b study is a six-month, multi-center, randomized, double-blind, placebo-controlled, dose-ranging clinical study in refractory gout patients with or without tophi, to evaluate the efficacy and safety of a 10, 30, or 60 mg tablet dose of SAP-001. The study enrolled 87 patients from 21 US sites.

The Primary objective is to assess the effectiveness of SAP-001 in lowering serum urate levels in gout patients that are refractory to standard-of-care Xanthine Oxidase Inhibitor (XOI) therapy. Secondary study objectives include safety and tolerability assessments and frequency of gout flares among others.

About Shanton Pharma

Shanton Pharma is a privately held, clinical-stage biotech founded in 2016 by experienced pharma entrepreneurs, with a research focus on unmet needs associated with hyperuricemia and gout. The company is headquartered in Singapore with research and development activities in the US, China, and Singapore.

SAP-001 is Shanton’s lead investigational compound for once-a-day oral urate-lowering therapy that targets refractory gout. SAP-001’s urate lowering properties are based on a unique mechanism-of-action and the product has shown unparalleled efficacy and safety in Phase 1 and Phase 2a clinical studies in gout patients with hyperuricemia, and now also has shown Best-in-Class efficacy and safety in gout patients with hyperuricemia refractory to Standard of Care Xanthine Oxidase Inhibitor therapy.

To learn more about Shanton Pharma, go to https://shantonpharma.com.

References

  1. Yokose C, McCormick N, Lu N, et al. Trends in Prevalence of Gout Among US Asian Adults, 2011-2018. JAMA Netw Open. 2023.
  2. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015.
  3. Clarivate Incidence and Prevalence Data Base

Media Contact

Pieter de Ridder
VP of Business Development
media@shantonpharma.com 

Dahsheng Chemical Celebrates 80th Anniversary with the Launch of DURAPONTEX® eN35, a Revolutionary Supercritical Fluid Foaming Insole

DURAPONTEX® eN35 Insole Provides Unmatched Cushioning and Rebound for High-Impact Sports

PORTLAND, Ore., March 28, 2025 /PRNewswire/ — Dahsheng Chemical (DSC®), a global leader in performance foam manufacturing, marks its 80th anniversary with the debut of its latest insole innovation: DURAPONTEX® eN35. Utilizing DSC’s advanced supercritical fluid foaming technique, the cutting-edge DURAPONTEX® eN35 is engineered to withstand the demands of high-impact and jump-dominant sports while delivering ultra-lightweight performance. With the launch of DURAPONTEX® eN35, DSC continues its 80-year legacy of innovation, pushing the boundaries of material science to redefine what’s possible in athletic footwear.

Dahsheng Chemical celebrates 80th anniversary with the launch of DURAPONTEX® eN35, a revolutionary supercritical fluid foaming insole.
Dahsheng Chemical celebrates 80th anniversary with the launch of DURAPONTEX® eN35, a revolutionary supercritical fluid foaming insole.

“We designed the DURAPONTEX® eN35 for the athlete who demands high-energy return in a lightweight package,” said Fennie Wei, COO of Dahsheng Chemical (DSC®). “By leveraging our own proprietary DURAPONTEX® N-Series supercritical fluid foaming technology and specialized formulation, the DURAPONTEX® eN35 exhibits a significant advancement in lightweight technology. This new material offers powerful energy rebound, yet in an even lighter form, which the elite athlete craves.”

DSC was the first brand to utilize supercritical fluid foaming technology in the development of an insole at scale with its DURAPONTEX® N-Series. Supercritical fluid foaming has revolutionized performance footwear, offering superior energy return, lightweight comfort, and durability. Through rigorous testing and precision engineering, DSC has optimized its supercritical fluid foaming technique to deliver an insole that provides a balance of resilience, responsiveness, and comfort—setting a new benchmark in performance footwear. DSC’s supercritical fluid foaming process has redefined what performance and support underfoot feels like, and is one of the most sought-after technologies for the elite athlete.

DURAPONTEX® N-Series is DSC’s specialized closed-cell foam compound, crafted with DSC’s unique supercritical fluid foaming technology, infused with carbon dioxide (CO2) or nitrogen (N2). The sophisticated process requires consistent high temperature and pressure control. Carbon dioxide or nitrogen gas emissions are infused, leading to an innovative transformation. As a result, a soft foam cell is made with evenly spaced microscopic bubbles and air pockets, creating an ultra-lightweight insole that delivers unparalleled resiliency and responsiveness.

As part of the DURAPONTEX® N-Series, DURAPONTEX® eN35 is designed to deliver resiliency and rebound for high-impact and jump-dominant sports including basketball, volleyball, and tennis, among others. DURAPONTEX® eN35 is ultra-lightweight with a low-density performance and 100% recyclable foam. The high-rebound insole is designed to adapt to a wide range of stresses without compromising its structural integrity and deliver consistent high energy return.

DSC’s proprietary supercritical fluid foaming compound was tested, refined, and optimized last year through DSC’s Athlete Engagement Program at the Portland Track Festival. Participants tried on the DURAPONTEX® N-Series and DSC received positive feedback on the foam’s lightweight comfort, durability, and powerful energy return. This valuable feedback drives DSC’s commitment to continuous innovation, ensuring that every product meets the demands of high-performance athletes.

Since its founding in 1945, Dahsheng Chemical (DSC®) has been a leader in foam innovation for the sports and bedding industries. Known for its premium comfort and performance foam DURAPONTEX® and DREAMCELL®, DSC partners with top brands and footwear manufacturers worldwide. By advancing innovation and pushing the limits of foam manufacturing, DSC® is dedicated to creating eco-friendly and advanced foam solutions that set new standards in the industry.

Visit www.dahsheng.com to learn more about Dahsheng Chemical (DSC®) and its commitment to sustainability and eco-innovation.

Media Contact:
Erin Patterson
t: +1-323-422-0274
e: erin.patterson@writetheskycomms.com

Camunda and Ashling Partners Announce Global Partnership to Drive Process Orchestration and Intelligent Automation

SYDNEY, March 28, 2025 /PRNewswire/ — Camunda, a global leader in process orchestration and automation, and Ashling Partners, one of the largest Intelligent Automation service providers, today announced a strategic global partnership. This collaboration combines Camunda’s powerful process orchestration and automation capabilities with Ashling Partners’ expertise in automation to accelerate digital transformation for organisations worldwide, with a particular focus on Australian engagements.

This partnership enables enterprises to automate and optimise complex business processes with efficiency, scalability, and intelligence. By integrating Camunda’s end-to-end orchestration platform with Ashling Partners’ deep knowledge of intelligent automation, businesses can unlock greater operational agility, enhance customer experiences, and drive innovation. A key goal of this partnership is to disrupt traditional monolithic automation platforms, enabling businesses to adopt a more agile, scalable, and modernised automation approach.

Ashling Partners recently expanded its global footprint by establishing its first international office in Melbourne, Australia, in March 2024. This strategic move, led by former Reveal Group partner Benjamin Lingard, underscores the firm’s commitment to delivering intelligent automation and process improvement solutions to the Australian market, with a focus on the manufacturing, finance, and healthcare sectors.

To further support the Australian market, Camunda and Ashling Partners are hosting an exclusive BFSI Front Office Round Table event, bringing together leading professionals from the banking, financial services, and insurance sectors across the country. This event will provide a platform for industry leaders to discuss best practices, emerging trends, and the future of automation in these critical sectors.

“We are thrilled to partner with Ashling Partners to help organisations automate mission-critical processes from end to end,” said Christina Christenson, VP global partners at Camunda. “Together, we enable enterprises to break down automation silos, orchestrate workflows across diverse technologies, and fully operationalize AI, ultimately leading to better operational efficiency and better customer experiences.”

“Joining forces with Camunda allows us to deliver cutting-edge process orchestration and automation solutions to our clients,” said Benjamin Lingard, Country Head (Australia) at Ashling Partners. “Our shared commitment to innovation and efficiency will help enterprises transform the way they work and create lasting competitive advantages.”

For more information, visit https://camunda.com/ and https://www.ashlingpartners.com/.

Media Contacts:

Charley Vokoun

+61431536271

charley.vokoun@ashlingpartners.com

Logo – https://laotiantimes.com/wp-content/uploads/2025/03/ashling_partners_logo.jpg 

SUNeVision Initiates MEGA IDC Phase Two Development

Hong Kong’s Largest Data Centre Built for the New AI Era

HONG KONG SAR – Media OutReach Newswire – 27 March 2025 – SUNeVision, the technology arm of Sun Hung Kai Properties (SHKP), today announced the commencement of construction for Phase Two of MEGA IDC in Tseung Kwan O.

(From left)SHKP Executive Director and SUNeVision Vice Chairman Allen Fung, SHKP Chairman & Managing Director and SUNeVision Chairman Raymond Kwok, Deputy Financial Secretary Michael Wong and SHKP Executive Director and SUNeVision Non-Executive Director Christopher Kwok officiate the initiation ceremony of MEGA IDC Phase Two.
(From left)SHKP Executive Director and SUNeVision Vice Chairman Allen Fung, SHKP Chairman & Managing Director and SUNeVision Chairman Raymond Kwok, Deputy Financial Secretary Michael Wong and SHKP Executive Director and SUNeVision Non-Executive Director Christopher Kwok officiate the initiation ceremony of MEGA IDC Phase Two.

As Hong Kong’s largest data centre service provider, SUNeVision operates a total of eight facilities across the territory, including MEGA IDC. Phase One of MEGA IDC, launched successfully last year, delivered approximately 500,000 square feet of gross floor area (GFA) and 50MW of power capacity. The facility has already attracted major cloud service providers and international banks to move in as customers. In response to strong market demand, construction of Phase Two has begun ahead of schedule. This phase will add around 350,000 square feet of GFA, with completion scheduled for 2026/2027.

The MEGA IDC project, to be completed in three phases, is the largest hyperscale data centre in Hong Kong. Phase Two will add approximately 350,000 square feet of GFA, with completion scheduled for 2026/2027.
The MEGA IDC project, to be completed in three phases, is the largest hyperscale data centre in Hong Kong. Phase Two will add approximately 350,000 square feet of GFA, with completion scheduled for 2026/2027.

The initiation ceremony for Phase Two was officiated by Deputy Financial Secretary Michael Wong, SHKP Chairman & Managing Director and SUNeVision Chairman Raymond Kwok, SHKP Executive Director and SUNeVision Non-Executive Director Christopher Kwok, and SHKP Executive Director and SUNeVision Vice Chairman Allen Fung. The ceremony marked a significant milestone for this key infrastructure project and was celebrated alongside prominent industry leaders.

Mr Michael Wong said at the ceremony that the government is fully committed to advancing AI development in Hong Kong. As Financial Secretary said in his Budget Speech, AI is at the core of developing new quality productive forces and Hong Kong should develop AI as a core industry. The investment in MEGA IDC, exceeding HK$15 billion, combined with tenant equipment investments, is expected to draw tens of billions in total investment to Hong Kong. He praised SHKP and SUNeVision for their confidence in Hong Kong’s future, demonstrated through significant investments that underscore their commitment to establishing Hong Kong as a leading data centre hub in the Asia Pacific, a commitment deserving full recognition and support.

Mr Raymond Kwok said: “Innovation and technology (I&T) is the cornerstone of new quality productive forces and plays a pivotal role in driving Hong Kong’s economic development. For years, SHKP has consistently invested in technological applications and state-of-the-art facilities to enhance Hong Kong’s new productive forces. As part of these efforts, SUNeVision is committed to building a world-class AI network infrastructure, strengthening Hong Kong’s connectivity with the mainland and global advanced technology markets.”

He added: “Despite the long investment return period for MEGA IDC, the Group remains committed, reflecting its role as a provider of ‘patient capital’ for Hong Kong and its confidence in the development of the data industry. In line with State Council Vice Premier Ding Xuexiang’s call to invest early, focus on the long-term growth and support ‘hard technologies’, SHKP will leverage its world-class data infrastructure to drive Hong Kong’s technological development. This will reinforce its role as a bridge connecting the mainland with the global technology world, enhancing Hong Kong’s competitiveness in the international AI arena.”

MEGA IDC – Hong Kong’s Largest Hyperscale Data Centre

The total investment in the MEGA IDC project exceeds HK$15 billion. Upon completion of the three phases, the facility will offer approximately 1.2 million square feet and of GFA and over 180MW of power capacity, making it the largest hyperscale data centre in Hong Kong. Designed to meet the space and power needs of cloud service providers and AI customers, this cutting-edge facility is at the forefront of fostering AI advancements and advancing Hong Kong’s I&T sector.

Mr Christopher Kwok said: “MEGA IDC, as an AI-ready data centre, stands out for its strategic location and advanced facility design. This site was specifically designated by the government for the development of high-tier data centres. Our infrastructure is highly resilient, with multiple backup power systems that not only meet the high energy demands of AI customers but also ensure ultra-low latency and uninterrupted operations. The facility’s physical security is built to the highest standards, with round-the-clock surveillance and biometric access controls, providing comprehensive protection for both the infrastructure and data. The SUNeVision team has travelled around the world to learn from the technical and management expertise of leading data centres worldwide, and conducted in-depth research into the specific needs of multinational financial institutions and cloud service providers. By implementing the highest standards in its facilities, MEGA IDC delivers comprehensive, high-quality services and is fully prepared to adapt to the evolving demands of the technology market.”

The infrastructure of SUNeVision MEGA IDC Phase One is highly resilient, with multiple backup power systems to ensure ultra-low latency and uninterrupted operations.
The infrastructure of SUNeVision MEGA IDC Phase One is highly resilient, with multiple backup power systems to ensure ultra-low latency and uninterrupted operations.

State-of-the-art Facility Captures Unprecedented AI Opportunities

The rapid evolution of AI has driven the growth of AI applications and inference technologies, creating a rising demand for high-quality, high-density data centres in Hong Kong. MEGA IDC is equipped with seven on-premise 132kV 75MVA transformers spanning Phase One and Phase Two, delivering stable, abundant, and high-quality power to meet present and future needs.

The data centre employs a modular design approach with a 5.7m slab-to-slab height and a robust 20kPA floor loading capacity, allowing customers to place their most advanced and mission-critical equipment.

Strategic Addition to SUNeVision’s Portfolio

Upon completion of the full MEGA IDC project, SUNeVision’s eight data centres will provide over 280MW of power capacity across three million square feet of GFA in Hong Kong. The development reinforces SUNeVision’s leadership in the digital infrastructure sector and positions the company to support both global and mainland cloud and AI companies as they expand in the Asia Pacific region.
Hashtag: #SUNeVision

The issuer is solely responsible for the content of this announcement.

About SUNeVision

SUNeVision (SEHK: 1686), the technology arm of Sun Hung Kai Properties (SEHK: 0016), is the largest data centre provider in Hong Kong. We provide industry-leading carrier and cloud-neutral data centre services with Asia’s number one connectivity. We connect providers of telecommunications, cloud, ISP, CDN, OTT from local, mainland China and global with enterprises of different businesses on our Asia leading data centre ecosystem.

SUNeVision forms MEGA Campus by extending the connectivity edge from highly connected MEGA-i to other high-tier data centres, including MEGA Gateway, MEGA IDC, MEGA Plus and MEGA Two. Facilities on MEGA Campus are interconnected through a dedicated dark fibre network and around 15,000 cross-connects. Together with City PoPs of major submarine cables in our facilities, we enable our customers for direct connections to multi-cloud platforms and multi-cloud exchanges with the best connectivity in town. The addition of cable landing stations HKIS-1 and HKIS-2 to our data centre portfolio will provide a one-stop-solution to cable owners and users, strengthening our position as the leading connectivity hub in Asia. We are committed to supporting Hong Kong as a regional information hub and a strategic gateway to mainland China.

For more information, please visit SUNeVision’s , or .

Uni-Bio Science Group Limited Announces 2024 Annual Results

Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical Markets


HONG KONG SAR – EQS Newswire – 27 March 2025 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2024 (the “Period”).

Key Accomplishments in 2024

During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. The Group recorded a 14.1% year-on-year (“YoY”) increase in revenue, reaching approximately HK$553.0 million. With its approval in January 2024 and subsequent launch in March 2024, Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations.

2. Profit for the Year soared by16.8% YoY to approximately HK$82.8 million, marking a historic high. These results reaffirm the Group’s solid market position and its ability to deliver sustainable, high-quality growth as a leading biopharmaceutical company.

3. The board of directors (“Board”) has declared a dividend payment for 2024 of HK$0.277 cents per share, marking the historic first for the Company. This is particularly encouraging, as it represents an important milestone for a research-oriented biopharmaceutical company. The Board is also pleased to announce the approval and adoption of a dividend payout policy of no less than 20% of its net profit for the current year.

4. In January 2024, the China National Medical Products Administration (“NMPA”) officially approved the launch of Bogutai®, marking a major breakthrough for the Group in osteoporosis and orthopedic disease management. Since its market debut in early 2024, Bogutai® has gained remarkable traction, achieving a patient retention rate exceeding 70%.

5. In December 2024, the Group successful launch its self-developed medical aesthetics product, 肌顏態®. The recombinant collagen dressing, developed in collaboration with Chongqing Minji Medical Device Co., Ltd., received Class II medical device approval, reinforcing the Group’s commitment to innovative skin repair solutions.

6. In January 2024, the NMPA officially accepted the marketing application for Diquafosol Sodium eye drops, marking a key milestone in the Group’s ophthalmology drug pipeline. During the Year, the Group has already submitted additional data to the Center for Drug Evaluation (CDE). Diquafosol Sodium is expected to receive the marketing approval in the first half of 2025.

7. During the Year, the Group completed the pharmaceutical research and pre-Bioequivalence studies of Esaconazole sulfoate capsules. The formal Bioequivalence trials has been initiated in 2025 to accelerate the launch process.

8. In May 2024, the Group cooperated with Great Bay Bio (GBB) and Pebble Accelerator, a subsidiary of Tigermed to joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, we seek to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical pipeline, and ultimately, commercialization.

Annual Results

In 2024, the Group recorded a revenue of approximately HK$553.0 million, representing an increase of 14.1% YoY. The increase in revenue was mainly attributable to the favorable sales performance of the Group’s newly launched product Bogutai®. The Group’s newly launched product Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations. Pinup® recorded a decrease of 2.9% in revenue from approximately HK$247.4 million to approximately HK$240.3 million for the Year. During the Year, the Group was re-selected for the centralized procurement, with a validity period of two years. However, the Group adopted a more selective approach to supplying hospitals in response to certain local policy adjustments. During the Year, revenue generated from GeneTime® was approximately HK$197.9 million, representing an increase of 6.7% YoY. The increase was attributed to the expansion of the Group’s hospital network and additional sales channels beyond hospitals, such as pharmacies and e-commerce platforms. GeneSoft® recorded an increase in revenue from approximately HK$41.3 million to approximately HK$42.5 million, representing an increase of 2.9% YoY. Revenue from Boshutai® declined from approximately HK$10.4 million to approximately HK$9.4 million, representing a decrease of 10.2%. During the Year, Boshutai® was successfully included in the centralized procurement by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years, which secured the Group with new in-hospital orders.

Gross profit was approximately HK$461.1 million, representing an increase of 17.4% as compared with approximately HK$392.8 million in 2023, and gross profit margin increased by 2.4 percentage points YoY to 83.4%. The Group has optimized its supply chain to enhance raw material procurement competitiveness, improve scaling efficiency, and reduce procurement and production costs, achieving greater economies of scale. Thanks to the Group’s diligent internal control, general and administrative expenses accounted for merely 9.2% of revenue in 2024 as compared with 9.8% in 2023. The selling and distribution expenses for the Year also decreased to 47.3% of revenue from 49.8% in 2023, mainly due to the marketing expenses decreased. The R&D expenses increased by47% YoY to approximately HK$52.3 million, aligning with the Group’s multi-pipeline research progress.
The Group achieved another year of record-breaking profit of approximately HK$82.8 million for the Year, marking an impressive increase of 16.8% YoY. This remarkable achievement was fueled by the successfully launch of the new product Bogutai®, along with the consistent demand for other marketed drugs, stringent cost management, and ongoing supply chain enhancements. This sustained profitability strengthened the Group’s foundation for long-term success in the years ahead.

Prospects

Recent advancements in biotechnology, coupled with strong government support, position China’s pharmaceutical landscape for substantial growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, according to the IMARC Group. This expansion is driven by technological innovations and a growing elderly population increasingly susceptible to chronic conditions such as diabetes, which boosts pharmaceutical demand. Concurrently, the aesthetic medical sector is emerging as a significant market force, with forecasts indicating a CAGR of 10% to 15% from 2024 to 2027, primarily fueled by rising beauty standards and increased spending among individuals with moderate to high incomes. With the two industries being the Group’s core R&D focuses going forward, it showcases a great potential for the Group to rapidly grow and capture the market shares.

Mr. Kingsley Leung, Chairman of Uni-Bio Science commented, “I am proud to announce that we have reached significant milestones this year, both financially and operationally. As our efforts begin to bear fruit, I am deeply grateful for the unwavering, long-term support of our shareholders. In recognition of this, I am delighted to share two landmark decisions: the declaration of our inaugural dividend and the establishment of a forward-looking dividend payout policy of no less than 20% of its net profit for the current year. These actions reaffirm our steadfast commitment to delivering on our objectives while creating and sustaining value for our shareholders.

Looking forward, we remain steadfast in our commitment to innovation and seizing opportunities within both the pharmaceutical and aesthetic medical sectors. Our vision has consistently focused on diversifying our product offerings while leveraging our strengths in endocrinology, ophthalmology, and dermatology. We are delighted to announce the successful launch of Bogutai® Following this milestone, we will continue to develop best-in-class products, including a PTH microneedle formulation that is less invasive and offers higher bioavailability, as well as a novel antibody drug for weight loss. Significant advancements have also been made in our series of EGF products. Preparations for pilot plant testing of the EGF hydrogel are underway, and Diquafosol Sodium Eye Drop slated for launch in the second quarter of 2025. Additionally, The formal Bioequivalence trials for Esaconazole sulfoate capsules has been initiated in 2025 to accelerate the launch process.

In the aesthetic medical segment, we are excited about the launch of肌顏態® in late December 2024. Building on this momentum, we will accelerate the introduction of other new product lines in 2025 based on Skbrella™ FN. Additionally, we plan to introduce collagen and beauty peptides as advanced skincare raw materials this year. By leveraging our expertise in GeneTime® and 肌顏態®, we aim to create a comprehensive skincare solution for emergency skin repair and stabilization. To foster our product innovation, we are utilizing two new key technology platforms: advanced synthetic biology platform and hydrogel technology. These platforms are expected to drive our product expansion.

To enhance our reach and support product launches, we are expanding our sales channels beyond traditional public and private hospital networks to include pharmacies, online platforms, and aesthetic medical institutions. We are also exploring international markets to bolster our global presence. By adopting a diversified distribution strategy, the Group aims to secure future sales growth while reducing its dependence on regional markets and traditional channels. In support of our company’s growth, the infrastructure for our new factory in Dongguan was fully completed in 2024, marking a significant milestone in our expansion plans. A state-of-the-art BFS packaging line has also been featured, which we believe will enable the Group to command a premium in the market. With these strategic focuses and our commitment to rapid advancement, the Group is well-positioned to solidify its leadership in these dynamic industries and achieve lasting success in the years ahead.”

Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

For further information, please contact:

Commerce Dot Com Leads CSR Effort to Celebrate Ramadan with Lanoh Tribe

PERAK, MALAYSIA – Media OutReach Newswire – 27 March 2025 – The residents of Kampung Air Bah, Lenggong, Perak; mostly Muslims from the Lanoh indigenous tribe warmly welcomed the visit from Commerce Dot Com (CDC) as they carried out a corporate social responsibility (CSR) programme within the ESG framework on 20 and 21 March. The initiative is part of CDC’s annual efforts to strengthen ties with local communities, while nurturing compassion, unity, and humanity among its staff.

Volunteers and members of the Lanoh community gathered in unity for Tarawih prayers, sharing a spiritually uplifting moment that deepened bonds and reflected the true spirit of Ramadan.
Volunteers and members of the Lanoh community gathered in unity for Tarawih prayers, sharing a spiritually uplifting moment that deepened bonds and reflected the true spirit of Ramadan.

Titled “Ukhuwah Ramadan: Santuni Masyarakat Orang Asli”, the Ramadan-themed programme was executed with a unique approach. According to Djuan Onn Abdul Rahman, Vice President of Corporate Communications and Marketing at CDC, “This programme stands out from our other past initiatives.

In collaboration with the Bambusa Foundation, we had the opportunity to directly engage with the Orang Asli Muslim community here, reaching out across all age groups. Our presence carried a simple message, sharing the daily routines of Muslims during the fasting month of Ramadan. In my view, even though we were there for just one night, we were able to enliven the spirit of Ramadan.”

The initiative gathered over 300 members of the Lanoh tribe to participate in various activities, including a communal iftar, health screenings, fun games and dental care sessions conducted by the University College MAIWP International.

The programme also received strong support from Universiti Malaya students, MAIWP staff and students, including CDC employees, with a total of 35 volunteers participating in the initiative.

Meanwhile, Mohd Rizal Alias, Tok Batin which is head of the Lanoh community, expressed his appreciation to CDC for organising memorable Ramadan programme. He described the event as a new and enriching experience for the villagers, offering valuable exposure and something they could emulate in their daily lives.

This initiative underscores CDC’s commitment to sustainable community engagement and highlights its continued efforts in making a positive difference through impactful CSR activities.Hashtag: #commercedotcom #cdc #CSR #orangasli #ramadan #Cultural #heritage




The issuer is solely responsible for the content of this announcement.

Commerce Dot Com Sdn Bhd

Established in 1999 as a procurement solutions provider, Commerce Dot Com Sdn. Bhd. (CDC), has established itself as among the leading procurement solutions providers in Malaysia and has a well-earned reputation for providing exceptional services through its innovative solutions.